Key facts
- This page summarizes Abraham N. Oler's Form 4 filing for Onconova Therapeutics, Inc. (TRAW).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 31 Jan 2022, 07:41.
Abraham N. Oler - 28 Jan 2022 Form 4 Insider Report for Onconova Therapeutics, Inc. (TRAW)
- Reporting relationship
- SVP Corp Dev & Gen Counsel
- Issuer ticker
- TRAW
- Reported as of
- 28 Jan 2022
- Net transaction value
- +$2,505
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2022, 07:41:50 UTC
- Prior SEC filing
- 24 Jan 2022
- Next SEC filing
- 09 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Guerin as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Abraham N. Oler filed Form 4 for Onconova Therapeutics, Inc. (TRAW) on 31 Jan 2022.
Change
- Previous filing in this sequence was filed on 24 Jan 2022.
- Current net transaction value: +$2,505.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ONTX
transaction
Common Stock
Purchase
- Transaction value
- $2,505
- Shares
- +1,500
- Change %
- +6.5%
- Price
- $1.67
- Shares after
- 24,514
- Date
- 28 Jan 2022
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The purchases reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Footnote F2
Includes 10,333 shares held by the Abraham Oler Living Trust U/T/A DTD 07/27/2012, of which the reporting person is a trustee.